In a five year study, 55 patients with radiolucent gall stones were treated with the combination of 7*5 mg chenodeoxycholic acid (CDCA) and 5 0 mg ursodeoxycholic acid (UDCA)/kg/daythat is, half the monotherapeutic doses. Side effects were few but four patients could not tolerate the prescribed bile acids because of diarrhoea or nausea. Analysis of fasting duodenal bile confirmed that CDCA+UDCA converted supersaturated into unsaturated bile but the saturation indices did not predict the dissolution response. By actuarial analysis, the confirmed (by ultrasound x 2) complete gail stone dissolution rates in all 55 patients were mean (SEM) 29 (7)% at 12 and 44 (8)% at 24 months. The advent of routine computed tomography before treatment enabled comparison of dissolution efficacy in those screened by computed tomography (n=24), whose maximum gail stone attenuation was <100 Hounsfield units, with that in those ndt screened (n=29). Although stone size and number were comparable, patients screened by computed tomography had significantly better dissolution rates (p<0025) than those not screened in this way. At 12 months, partial or complete gall stone dissolution rates were 93 (7)% in the screened and 55 (11%) in the nonscreened patients. At 18 months, complete dissolution rates were 64 (12%) and 20 (9)% respectively. Computed tomography before treatment is cost effective in selecting those patients likely to achieve gall stone dissolution on treatment with UDCA+CDCA.
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Monotherapy with oral chenodeoxycholic acid (CDCA) or ursodeoxycholic acid (UDCA) is moderately effective in dissolving cholesterol rich gall stones. ' ' The dose related side effects of diarrhoea, hypertransaminasaemia,5 and hypercholesterolaemia,6 however, have limited the acceptability of CDCA as a gall stone dissolving agent. UDCA causes minimal side effects but in our experience its efficacy in dissolving gall stones completely is less than that of CDCA, partly because of secondary gall stone calcification. 4 Furthermore, although less UDCA than CDCA is required to desaturate bile7-9 and dissolve gall stones, the cost of monotherapy with UDCA is somewhat greater than that of CDCA. For these reasons, several groups"8-'6 have advocated the combination of CDCA and UDCA, each at half their monotherapeutic doses, with the aim of maintaining dissolution efficacy while minimising side effects. We began using CDCA plus UDCA for gall stone dissolution in 1984 and report here the results of a five year study with this combination in 55 patients.
We,'7 and others, '8" 19 have recently shown that no less than 50% of gall bladder stones which are lucent by conventional radiology (plain x ray with or without oral cholecystography), look dense on computed tomography. These stones have high Hounsfield unit (HU) attenuation values and contain calcium in amounts that render complete dissolution with oral therapy unlikely. Indeed, over the past three years we have routinely screened all patients being considered for non-surgical management of their gall bladder stones by localised scanning of the gall bladder, and have accepted patients for treatment with oral CDCA+UDCA only if their stones had a maximum computed tomographic attenuation of <100 HU. We show here that patients selected in this way have significantly higher partial and complete gall stone dissolution rates than those not so screened and suggest that routine computed tomography of the gall bladder before treatment is cost effective in predicting the dissolution response to oral bile acid therapy. Table I . Eight patients had previously been treated with oral bile acids and were given the combination of CDCA plus UDCA for management of either recurrent (n=2) or incompletely dissolved (n=6) stones.
All 55 patients had specific, gall stone related symptoms (biliary colic) and all chose oral bile acids in preference to surgery or other nonsurgical management options.20 The presence of gall bladder stones was usually diagnosed first by ultrasonography. In addition, however, all patients underwent oral cholecystography which included a preliminary plain abdominal x ray and, during the contrast study, erect and after fatty meal films. Liver function tests (serum albumin, bilirubin, alkaline phosphatase, and transaminase), serum lipids, and a full blood count were all normal before treatment. 29 patients who had not been screened (Fig 2) . By one year, the partial plus complete rate in screened patients with HU scores of < 100 was 93 (7%) compared with 55 (1l)% in those who had not been screened.
Over all time points, complete gall stone dissolution rates were significantly better in the screened group (p<0025). At 12 months, the complete dissolution rates were 50 (12)% in the screened and 14 (8)% in the non-screened patients (Fig 3) . After eighteen months' therapy, 64 (12)% of the screened patients showed complete dissolution compared with only 20 (9)% of the unscreened patients (p<001). As shown in Table I 24 Figure 3: Complete gall stone dissolution rates (mean (SEM)) in the two subgroups of(i) 24 patients screened by computed tomography and (ii) 29 patients with no pretreatment computed tomography. stones in selected patients. Furthermore, they show that routine computed tomography before treatment, to exclude patients with calcified gall stones on the basis of a maximum stone attenuation value >100 HU, significantly increases the probability complete stone dissolution.
The combination of CDCA and UDCA has been used in recent years by several groups""'6 in order to reduce the side effects of CDCA and the cost of UDCA while maintaining the efficacy of gall stone dissolution. Podda et all' have clearly shown in a prospective randomised trial that the combination of CDCA and UDCA results in better dissolution rates than UDCA alone.
UDCA and CDCA act somewhat differently to reduce biliary cholesterol saturation but, as our study shows, when combined at a dose of 5 0 mg UDCAIkg/day and 7 5 mg CDCA/kg/day the two bile acids produce a highly significant reduction in the mean biliary cholesterol saturation index from 1-32 to 0 74. This change in the saturation index is similar to that shown in other studies with the combination of the two bile acids'0"516 but does not take into account cholesterol present in biliary vesicles or in other non-micellar forms.
In the pooled group (computed tomography screened plus those not screened) of 55 patients, the complete dissolution rate after two years of UDCA plus CDCA treatment was only 44 (8)%. However, this figure is biased by the outcome in the subgroup of patients screened by computed tomography. Had they been excluded, the two year complete dissolution rate in the patients without computed tomography would have been only 33 (11) % This is a lower figure than that obtained by others with the combination of UDCA and CDCA. For example, Podda et all' reported a complete dissolution rate of60 (6)% at 24 months. However, their patients were highly selected in that almost half (29 of 60) had small floating stones. Other investigators have shown lower mean dissolution rates of 25%12 and 27%16 after 24 months' treatment.
In our study, complete dissolution was defined rigorously by two normal ultrasound examinations. This approach is likely to result in lower but more accurate dissolution rates than those obtained using less stringent criteria. Thus, in another study from our unit in which UDCA alone was given in a dose of [8] [9] [10] mg/kg/day, complete dissolution occurred in 25-30% of patients when defined by oral cholecystography but in only 17-19% when defined by ultrasonography.4 This compares with an overall complete dissolution rate of 38% diagnosed by oral cholecystography in a third group of comparably selected patients from our unit who were treated with CDCA alone.2
In the present study, the combination of UDCA and CDCA was generally well tolerated. Although 25% of the patients reported some diarrhoea, it was usually mild and transient. This compares with an incidence of about 50% in patients given CDCA alone. In contrast, computed tomography is well accepted by patients and although it is expensive, it involves minimal exposure to x irradiation. As shown by the present results, it had a major impact on dissolution efficacy when used routinely to exclude patients with calcium containing stones that were judged unlikely to dissolve completely. Based on previous studies from our unit'7 in which we related the maximum pretreatment gall stone HU score measured in vivo to gall stone composition and dissolvability -both measured in vitro in stones retrieved at cholecystectomy -in the present study, we chose a cut off point in maximum gall stone attenuation of 100 HU. This corresponds to a stone total calcium content of only 3% by weight, but even this small amount of calcium seems to be enough to impair complete dissolution with contact solvents such as MTBE.27 However, measurement of gall stone attenuation by in vivo computed tomography is not precise28 and there is intrapatient, intramachine, and intermachine variability which we estimate to be approximately ± 10 HU overall.
We believe that the observed improvement in dissolution efficacy as a result of routine computed tomographic screening before treatment, is due solely to the exclusion of patients with calcium containing stones. Thus, the patient and gall stone characteristics were comparable in patients screened and not screened by computed tomography. Furthermore, there was no bias as a result of including previously treated patients in the two treatment groups. In the present study, there were too few patients with recurrent stones to extend the results of previous studies from our own unit29 and elsewhere30 which suggest that most, but not all, recurrent stones are small, cholesterol rich, and easily dissolvable.
The present report is important not only because it extends the results of previous studies in which the combination of oral UDCA and CDCA has been used as the sole treatment for gall bladder stones, but also because we3 ' 
